Mark Schoenberg - 08 Jun 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
08 Jun 2025
Net transactions value
-$38,044
Form type
4
Filing time
11 Jun 2025, 09:14:14 UTC
Previous filing
04 Feb 2025
Next filing
30 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Schoenberg Mark Chief Medical Officer 400 ALEXANDER PARK DRIVE, PRINCETON /s/ Jason D. Smith, Attorney-in-Fact 10 Jun 2025 0001763581

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +10,000 +6.7% 158,540 08 Jun 2025 Direct F1
transaction URGN Ordinary Shares Sale $38,044 -5,162 -3.3% $7.37 153,378 09 Jun 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -10,000 -50% $0.000000 10,000 08 Jun 2025 Ordinary Shares 10,000 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024.